(Reuters) -Johnson & Johnson said on Monday it has discontinued a late-stage study testing its experimental drug to treat a ...

Johnson & Johnson (NYSE:JNJ) said it has discontinued a Phase 2 study of its drug TAR-200 for the treatment of ...

J&J acquired rights to the silicone-based drug delivery service used in TAR-200, which allows for the continuous release of ...

The sun has set on Johnson & Johnson’s SunRISe-2 study. J&J called a halt to the phase 3 bladder cancer trial after an ...

"Johnson & Johnson discontinues Phase III study of treatment for bladder cancer" was originally created and published by ...

Researchers are a step closer to revolutionizing how doctors use radiotherapy to treat patients with muscle-invasive bladder ...

A new study in mice by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) has identified a promising drug ...

Prostate cancer is a major health concern for men worldwide — often developing without any immediate warning signs. Catching ...

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price ...

In response to the FDA request, there is a demonstrated duration of CR of 13.2% (9/68) at 540 days, 8.8% (6/68) at 630 days, 7.4% (5/68) at 720 days, 7.4% (5/68) at 900 days and 5.9% (4/68) at 1080 ...

The 2024 American Society for Radiation Oncology (ASTRO) annual meeting held in Washington D.C., between September 29 and ...

Researchers are a step closer to revolutionising how doctors use radiotherapy to treat patients with muscle-invasive bladder ...